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Abstract
 
Dendritic cells (DCs) form a network comprising different populations that initiate and differ-
entially regulate immune responses. Langerhans cells (LCs) represent a unique population of
DCs colonizing epithelium, and we present here observations suggesting that macrophage in-
flammatory protein (MIP)-3
 
a
 
 plays a central role in LC precursor recruitment into the epithe-
lium during inflammation. (a) Among DC populations, MIP-3
 
a
 
 was the most potent chemo-
kine inducing the selective migration of in vitro–generated CD34
 
1
 
 hematopoietic progenitor
cell–derived LC precursors and skin LCs in accordance with the restricted MIP-3
 
a
 
 receptor
(CC chemokine receptor 6) expression to these cells. (b) MIP-3
 
a
 
 was mainly produced by ep-
ithelial cells, and the migration of LC precursors induced by the supernatant of activated skin
keratinocytes was completely blocked with an antibody against MIP-3
 
a
 
. (c) In vivo, MIP-3
 
a
 
was selectively produced at sites of inflammation as illustrated in tonsils and lesional psoriatic
skin where MIP-3
 
a
 
 upregulation appeared associated with an increase in LC turnover. (d) Fi-
nally, the secretion of MIP-3
 
a
 
 was strongly upregulated by cells of epithelial origin after in-
flammatory stimuli (interleukin 1
 
b
 
 plus tumor necrosis factor 
 
a
 
) or T cell signals. Results of
this study suggest a major role of MIP-3
 
a
 
 in epithelial colonization by LCs under inflammatory
conditions and immune disorders, and might open new ways to control epithelial immunity.
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Introduction
 
Dendritic cells (DCs)
 
1
 
 are bone marrow–derived profes-
sional APCs with a unique ability to induce primary im-
mune responses. They represent a trace population of cells
found in virtually every tissue and biological fluid (for re-
views, see references 1–5). DCs exist at different matu-
 
ration stages interconnected by defined pathways of cir-
culation (1). In the periphery, immature DCs such as
Langerhans cells (LCs) capture antigens (6) and, under the
influence of inflammatory stimuli, subsequently migrate via
the lymphatic system or blood vessels. They reach second-
ary lymphoid organs and home to the T cell–rich areas,
where they present processed antigen to naive T cells and
generate antigen-specific primary T cell responses.
Recently, several studies, including ours, have demon-
strated that the traffic of DCs from the site of antigen cap-
ture to the draining lymphoid organs involves selective
chemokines active on maturing DCs through CC chemo-
kine receptor (CCR)7 (7–10). 6Ckine (secondary lymphoid
tissue chemokine [SLC], Exodus-2) expressed by lymphatic
vessels may direct into the lymph stream antigen-loaded
maturing DCs leaving the site of infection (11–14). Mature
DCs entering the draining lymph nodes might then be
driven into the paracortical area, in response to the produc-
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Abbreviations used in this paper:
 
 CCR, CC chemokine receptor; DC,
dendritic cell; HPC, hematopoietic progenitor cell; LAMP, lysosomal-
associated membrane protein; LC, Langerhans cell; MCP, monocyte
chemotactic protein; MIP, macrophage inflammatory protein; RANTES,
regulated upon activation, normal T cell expressed and secreted protein;
SCF, stem cell factor; SDF, stromal cell–derived factor. 
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tion of MIP-3
 
b
 
 (EBV-induced molecule 1 ligand chemo-
kine [ELC], Exodus-3) and/or 6Ckine by cells spread over
the T cell zone
 
 
 
(7, 15)
 
.
 
 This role of MIP-3
 
b
 
 and 6Ckine is
supported by the specific alterations in T cell and DC hom-
ing into lymph nodes observed in natural mutant mice de-
ficient for 6Ckine (16–18) and in CCR7 genetically defi-
cient mice (19).
In addition to the heterogeneity related to their stage of
maturation, DC populations differ in their origin and/or
function. In particular, human DC subsets have been re-
ported to exert different functions, with regard to the regu-
lation of B cell proliferation (20, 21) and the differentiation
of T cell responses towards type I or type II (22). Recently,
human circulating blood CD11c
 
2
 
 DC precursors (23, 24)
have been shown to correspond to natural IFN-
 
a
 
–produc-
ing cells (NIPCs), suggesting a role of this population dur-
ing viral infection (25). Finally, LCs represent a population
of DCs only found in epithelia, and whose specific func-
tion is not yet fully elucidated. Several studies have shown
that LCs are regulated independently from other DC pop-
ulations. In particular, TGF-
 
b
 
 has been identified as an es-
sential factor for the development of LCs both in vitro and
in vivo (26–30).
The selective recruitment of a specific DC population at
the site of infection will likely determine the type of im-
mune response initiated. Indeed, after pathogen invasion,
DCs are recruited at the site of inflammation as illustrated
in rat, where intratracheal antigen instillation induces accu-
mulation of DCs in the airway epithelium (31, 32). Al-
though several chemokines (monocyte chemotactic protein
[MCP]-3, MCP-4, MIP-1
 
a
 
, MIP-1
 
b
 
, MIP-3
 
a
 
, regulated
upon activation, normal T cell expressed and secreted pro-
tein [RANTES], stromal cell–derived factor [SDF]-1, thy-
mus-expressed chemokine [TECK], and macrophage-
derived chemokine [MDC]) have been reported to attract
immature DCs in vitro (7, 9, 33–36), their relative contri-
bution in normal and pathological conditions remains to be
understood. In this study, we have investigated the re-
sponse of LC precursors to chemokines. We show that
among all DC-attracting chemokines, MIP-3
 
a
 
 is the main
chemokine expressed by the epithelium that attracts LC
precursors. This specificity may open avenues for the un-
derstanding and eventually for the control of the specific
function of epithelial LCs.
 
Materials and Methods
 
Hematopoietic Factors, Reagents, and Cell Lines.
 
Recombinant
human (rh)GM-CSF (specific activity 2 
 
3 
 
10
 
6
 
 U/mg; Schering-
Plough) was used at a saturating concentration of 100 ng/ml.
rhTNF-
 
a
 
 (specific activity 2 
 
3 
 
10
 
7 
 
U/mg; Genzyme) was used at
an optimal concentration of 2.5 ng/ml (37). Recombinant hu-
man stem cell factor (rhSCF) (specific activity 4 
 
3 
 
10
 
5
 
 U/mg;
R&D Systems) was used at an optimal concentration of 25 ng/
ml. rhIL-4 (specific activity 2 
 
3 
 
10
 
7
 
 U/mg; Schering-Plough)
was used at a saturating concentration of 50 U/ml. Recombinant
human chemokines MIP-1
 
a
 
 (specific activity 2 
 
3 
 
10
 
5 
 
U/mg),
MIP-1
 
b
 
 (specific activity 10
 
4 
 
U/mg), RANTES (specific activity
 
10
 
4 
 
U/mg), MCP-1 (specific activity 10
 
4 
 
U/mg), MCP-2 (spe-
cific activity 10
 
4 
 
U/mg), MCP-3 (specific activity 10
 
4 
 
U/mg),
MCP-4 (specific activity 10
 
4 
 
U/mg), MIP-3
 
a
 
 (specific activity 4 
 
3
 
10
 
5 
 
U/mg), and SDF-1 (specific activity 2 
 
3 
 
10
 
5 
 
U/mg) were ob-
tained from R&D Systems.
 
Generation of DCs from Cord Blood CD34
 
1
 
 
 
Hematopoietic Pro-
genitor Cells or from Peripheral Blood Monocytes.
 
Cells bearing
CD34
 
1
 
 antigen were isolated from umbilical cord blood mono-
nuclear fractions through positive selection as described (37, 38),
using anti-CD34
 
1
 
 mAb (Immu-133.3; Immunotech), goat anti–
mouse IgG–coated microbeads (Miltenyi Biotec), and Midimacs
separation columns (Miltenyi Biotec). After purification, CD34
 
1
 
cells (80–99% purity) were cryopreserved in 10% DMSO.
Cultures were established in the presence of SCF, GM-CSF,
TNF-
 
a
 
, and 2.5% human AB
 
1
 
 serum, as described (37), in en-
dotoxin-free medium consisting of RPMI 1640 (GIBCO BRL)
supplemented with 10% (vol/vol) heat-inactivated fetal bovine
serum (Flow Laboratories), 10 mM Hepes, 2 mM 
 
l
 
-glutamine,
5 
 
3 
 
10
 
2
 
5 
 
M 
 
b
 
-mercaptoethanol, 100 
 
m
 
g/ml gentamicin (Scher-
ing-Plough). After thawing, CD34
 
1
 
 
 
cells were seeded for expan-
sion in 25–75-cm
 
2
 
 culture vessels (Linbro; Flow Laboratories) at
2 
 
3 
 
10
 
4
 
 cells/ml. Cells were used at day 6 where 15–30% of the
cells are CD1a
 
1
 
CD14
 
2
 
, representing LC precursors (37).
Monocytes were purified by immunomagnetic depletion
(Dynabeads; Dynal) after preparation of PBMCs followed by a
51% Percoll gradient. The depletion was performed with anti-
CD3 (OKT3), anti-CD19 (4G1), anti-CD8 (OKT8), anti-CD56
(NKH1; Coulter), and anti-CD16 (ION16; Immunotech) mAbs.
Monocyte-derived DCs were produced by culturing purified
monocytes for 6–7 d in the presence of GM-CSF and IL-4 (39).
 
Enrichment in CD11c
 
1
 
 DCs and CD11c
 
2
 
 DC Precursors from Pe-
ripheral Blood, and in LCs from Skin.
 
CD11c
 
1
 
 DCs and CD11c
 
2
 
cells were enriched as described previously from peripheral blood
(23, 24). Mononuclear cells were isolated by centrifugation over
Ficoll-Hypaque. Then, the depletion was performed with anti-
CD3 (OKT3), anti-CD19 (4G7), anti-CD14 (MOP9), anti-
NKH1 (Coulter), anti-glycophorine A (Immunotech), anti-CD16
(Immunotech), and anti-CD35 (Immunotech) to remove T and
B lymphocytes, monocytes, NK cells, and granulocytes from the
resulting low density cells by magnetic beads (anti–mouse Ig–
coated Dynabeads; Dynal). All of the depletion procedure was
performed in the presence of 0.5 mM EDTA. The enriched pop-
ulation contained between 20 and 35% DCs identified by their
expression of HLA-DR (Tricolor; Becton Dickinson) and the
lack of FITC-labeled lineage markers CD3, CD14, CD15,
CD16, CD20, and CD57.
Epidermal cell suspensions were obtained from normal skin
patients undergoing reconstructive plastic surgery of breast or ab-
domen, as described elsewhere (40). LC enrichment was
achieved by successive density gradient centrifugation steps and
depletion of basal keratinocytes. The isolated cells contained 55–
75% CD1a
 
1
 
 LCs.
 
Nonhematopoietic Cell Culture.
 
Human primary keratinocytes,
dermal fibroblasts, and endothelial cells (human umbilical vein
endothelial cells) were purchased from Clonetics and cultured in
keratinocyte (KGM-2), fibroblast (FGM), or endothelial cell
(EGM-2) growth media (Clonetics). For production of superna-
tants, cells were seeded at 1–2 
 
3 
 
10
 
4
 
 cells per ml, and after 3–5 d
(80% confluence), fresh medium was added in the presence or ab-
sence of activators (IL-1
 
b
 
 at 10 ng/ml and TNF-
 
a
 
 at 2.5 ng/ml).
Supernatants were harvested after 48 h. A similar procedure
was used for cell lines of various origins (American Type Cul-
ture Collection), including the renal cell carcinoma lines CHA 
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and VER (generated by Léon Bérard Center, Hospital, Lyon,
France).
 
Analysis of CCR6 Expression by FACS
 
®
 
.
 
Expression of CCR6
was determined using an mAb against CCR6 (R&D Systems).
On CD34
 
1
 
-derived DCs, monocyte-derived DCs, and freshly
isolated skin LCs, double staining was performed with anti-
CD1a–FITC. On monocytes, double stainings were performed
with anti-CD14–FITC. On blood DCs, triple stainings were per-
formed with anti–HLA-DR–Tricolor (Becton Dickinson), anti-
CD3, -CD14, -CD16, -CD19, -CD20, -CD56–FITC (Becton
Dickinson), and anti-CCR6–PE (R&D Systems).
 
Chemotaxis Assay.
 
Transwell (5-
 
m
 
m-pore; Costar) experi-
ments were performed to characterized heterogeneous popula-
tions. Serial dilutions of chemokines or supernatants were added
to 24-well plates. 5 
 
3 
 
10
 
5
 
 cells were added to transwell inserts.
Plates were incubated for 1.5 h at 37
 
8
 
C. After removal of the
transwell inserts, migrated cells were counted and stained for flow
cytometry, to either differentiate between CD1a
 
1
 
 and CD14
 
1
Figure 1. MIP-3a is the most po-
tent chemokine to induce the selec-
tive migration of CD1a1 LC precur-
sors derived from CD341 HPCs.
CD341 HPCs were cultured in the
presence of SCF1GM-CSF1TNF-a
for 6 d. Migration assays were per-
formed by seeding 5 3 105 cells in
5-mm-pore transwells for 1.5 h. The
migrated cells were analyzed for
CD1a and CD14 expression by
FACS® after double staining. Results
are expressed as the number of mi-
grated cells measured by FACS®, and
represent the means of optimal re-
sponses for each chemokine obtained
in 10 independent experiments. A
shows the migration of the total DC
precursors (both CD1a1 and CD141
subpopulations) and B that of CD1a1
LC precursors alone. Chemokines
were used at their optimal concen-
tration, from 1 to 500 ng/ml.
Figure 2. Only LC precursors derived from
CD341 HPCs and isolated skin LCs migrate in
response to MIP-3a and express CCR6.
CD341 HPC–derived CD1a1 LC precursors,
monocyte-derived DCs, blood CD11c1 DCs,
blood CD11c2 DC precursors, and epidermal
LCs were isolated as described in Materials and
Methods. (A) Migration assays were performed
by seeding 5 3 105 cells in 5-mm-pore trans-
wells for 1.5 h. Migration in response to MIP-
3a was assessed for all populations; the positive
controls were RANTES for CD341 HPC–
derived CD1a1 LC precursors and epidermal
LCs, MCP-1 for monocyte-derived DCs
(Mono-DC), and SDF-1 for blood CD11c1
DCs and blood CD11c2 DC precursors. The
migrating cells were analyzed for CD1a and
CD14 expression for CD341-derived DCs and
monocyte-derived DCs. Blood DCs were ana-
lyzed by triple staining for HLA-DR, CD11c,
and lineage markers by FACS®. Skin-derived
LCs were enumerated and identified based on
morphology. Results are expressed as migration
index compared with the control (medium
alone), and represent the means obtained in 4–10
independent experiments. (B) The expression
of CCR6 was determined by double staining
with CD1a for CD341-derived CD1a1 LC pre-
cursors, monocyte-derived (Mono-der) DCs,
skin LCs, with CD14 for monocytes, and by
triple staining with HLA-DR and lineage
markers for blood DCs. The results are repre-
sentative of 5–10 experiments.708 Inflammation-induced MIP-3a Recruits Langerhans Cell Precursors among DCs
DC precursors (from CD341 hematopoietic progenitor cells
[HPCs]) or HLA-DR1Lin2CD11c1 circulating blood DCs and
HLA-DR1Lin2CD11c2 blood DC precursors.
In Situ Hybridization. In situ hybridization for MIP-3a was
performed as described (7, 41). Coupled primers were used for
amplifying by reverse transcription PCR the majority of the open
reading frame of the MIP-3a gene. Sense and antisense probes
for MIP-3a were radiolabeled with 35S-UTP, and then partially
degraded by alkaline hydrolysis. 6-mm cryostat sections of human
tonsil and normal, lesional, and nonlesional psoriatic skin were
Figure 3. In vivo MIP-3a is
expressed by epithelial cells lin-
ing the crypts of inflamed tonsils
and is surrounded by CCR61
cells. (A–C) Immunohistochem-
istry of human tonsils per-
formed with anti–hMIP-3a
polyclonal antibody (red) re-
veals that MIP-3a is strongly
and exclusively expressed within
inflamed epithelial crypts. Dou-
ble staining with anti–hMIP-3a
polyclonal antibody (red) and
anticytokeratin (blue) (A) or
anti–E-cadherin mAb (blue) (B)
shows that MIP-3a is produced
by a subset of epithelial cells lin-
ing the crypts in tonsils. More-
over, double immunostaining
performed with MIP-3a–spe-
cific polyclonal antibody (red)
and anti-CD1a mAb (blue) (C)
reveals that MIP-3a–expressing
epithelial cells colocalize with
CD1a1 LCs within the inflamed
crypts, a site of pathogen entry.
(D) Focal accumulation of
CCR61 cells (red) is directly ad-
jacent to MIP-3a–expressing
epithelial cells within the areas of
E-cadherin1 cells (blue). The
specificity of MIP-3a immunostaining was demonstrated either by using isotype controls or by preincubating the anti–MIP-3a polyclonal antibody
with the recombinant MIP-3a protein; in both conditions, no staining was detected (data not shown). C, epithelial crypt of tonsils. Original magnifica-
tions: (A and B) 3400; (C and D) 3200.
Figure 4. MIP-3a is selectively produced by epithelial cells. (A) Nonhematopoietic cells, including endothelial cells (human umbilical vein endothelial
cells), keratinocytes, and fibroblasts, were seeded at 1–2 3 104 cells/ml, and after 3–5 d of culture (80% confluence), cells were either activated by IL-
1b1TNF-a or left unactivated for 48 h. Monocyte-derived DCs and B lymphocytes were either activated by CD40L-transfected L cells (murine fibro-
blasts, CD40L L cells) or left unactivated for 24 h. Coculture with untransfected L cells was checked for the absence of MIP-3a production. Peripheral
blood monocytes and T lymphocytes were activated for 24 h in the presence of LPS and anti-CD3 plus anti-CD28, respectively. IL-1b1TNF-a did not
induce MIP-3a production by monocytes or monocyte-derived DCs (not shown). Supernatants were collected and measured for MIP-3a content using
a specific ELISA. (B) Keratinocyte supernatants were collected and measured for MIP-3a, MCP-1, MIP-1a, and RANTES contents using specific
ELISAs. Results shown are representative of five independent experiments.709 Dieu-Nosjean et al.
prepared on charged electrostatic slides (SuperFrost/Plus; Poly-
labo) and fixed with cold acetone and 4% paraformaldehyde fol-
lowed by 0.1 M triethanolamine/0.25% acetic anhydride. The
sections were hybridized overnight at 508C (2–3 3 106 cpm/
slide), RNase A treated, and after washing under stringent condi-
tions, were exposed for 40 d. After development, the sections
were stained with Harris hematoxylin.
Immunohistochemistry. Frozen 6-mm tissue sections (human
tonsils and skin) were fixed in acetone and in 4% paraformalde-
hyde before the immunostaining. To block the nonspecific activ-
ities, sections were pretreated with avidin D and biotin solutions
(Blocking kit; Vector Laboratories) for 10 min each step and with
0.3% hydrogen peroxide (Sigma-Aldrich) for 15 min at room
temperature. After a brief washing in PBS, the sections were in-
cubated with blocking serum (2% normal human serum) for at
least 30 min before adding both primary antibodies. Sections
were immunostained between two (simultaneously) or three (se-
quentially) of the following antibodies: anti–hMIP-3a goat poly-
clonal antibody (IgG; R&D Systems), anti-hCytokeratin (IgG1,
MNF116; Dako), anti–hE-cadherin (IgG1, HECD-1; Takara),
anti-hCD1a (IgG2a, Leu-6; Becton Dickinson), anti-hLangerine
(IgG1, DCGM4; Schering-Plough [42]), biotinylated anti–hDC-
lysosomal-associated membrane protein (LAMP) (IgG1, 104G4;
Schering-Plough [43]), anti-hCollagen type IV (IgG1, CIV22;
Dako), anti-hCCR6 (IgG2b, 53103.111; R&D Systems) mouse
mAbs for 1 h at room temperature in a humid atmosphere. The
binding of goat IgG was detected by biotinylated rabbit anti–goat
IgG followed by streptavidin-peroxidase, both included in the
Vectastain ABC kit (Goat IgG PK-4005; Vector Laboratories).
The binding of mouse IgG2a and IgG2b was revealed by biotiny-
lated sheep anti–mouse IgG2a (AB274; The Binding Site) and
IgG2b (AB275; The Binding Site), respectively, followed by Ex-
trAvidin–Horseradish Peroxidase (E2886; Sigma-Aldrich). The
binding of mouse IgG1 was revealed by rabbit alkaline phos-
phatase–labeled anti–mouse IgG (D0314; Dako) or by biotiny-
lated sheep anti–mouse IgG1 (AB274; The Binding Site) followed
by ExtrAvidin–Horseradish Peroxidase (E2886; Sigma-Aldrich)
at room temperature in a humid atmosphere. The peroxidase and
alkaline phosphatase activities were revealed using 3-amino-9-
ethylcarbazole (AEC) substrate (SK-4200; Vector Laboratories) or
diamino benzoate (DAB) substrate (Dako) and alkaline phos-
phatase substrate III (SK-5300; Vector Laboratories) for 1–10 min
at room temperature, respectively. Negative controls were estab-
lished by adding nonspecific isotype controls as primary antibod-
ies or by preincubating the primary antibody with the corre-
sponding recombinant protein (e.g., MIP-3a).
ELISA. Inbred BALB/c mice were immunized with three
successive intraperitoneal injections of complete Freund’s adju-
vant (Sigma-Aldrich), incomplete Freund’s adjuvant, or without
Freund’s adjuvant, with 50 ng of purified hMIP-3a obtained
from supernatants of hMIP-3a transient transfected COP5 cells.
Spleens were removed for fusion 3 d after an intravenous injec-
tion of hMIP-3a. Hybridization was carried out using the nonse-
creting myeloma cell line SP2/0-Ag8 with polyethylene glycol
1000 (Sigma-Aldrich). Human MIP-3a transient transfected
COP5 cells were cultured for 2 d in 96-well plates and fixed in
acetone. Then, hybridoma supernatants were harvested after 6 d,
then incubated for 30 min on fixed hMIP-3a transient trans-
fected COP5 cells. Antibody binding was then revealed with per-
oxidase-conjugated sheep anti–mouse IgG (Biosys) at a 1:200 di-
lution in PBS for 30 min at 378C. Positive hybridomas were
cloned by limiting dilution and expanded using a high density
culture system (Integra cell line CL1000; Integra Biosciences).
After sodium sulfate precipitation, the mAbs were purified by an-
ion exchange chromatography on a Hyper-D column and perox-
idase labeled (Sepracor). An ELISA was set up using one of the
anti–hMIP-3a mAbs, 319F6, as a capture mAb and a peroxidase-
coupled mouse anti–hMIP-3a mAb, 206D9, to reveal the cap-
tured hMIP-3a The sensitivity of the ELISA is 0.2 ng/ml of
MIP-3a and does not cross-react with all of the CC and CXC
chemokines tested (MIP-1a, MIP-1b, MIP-1d, MIP-3b, Eotax-
ine, 6Ckine, RANTES, MCP-1, thymus and activation-regu-
lated chemokine [TARC], MDC, TECK, SDF-1, IP-10,
monokine induced by IFN-g (MIG), and Lymphotactine from
R&D Systems).
The detection of others chemokines such as hMCP-1,
hRANTES, and hMIP-1a was realized by using commercial
ELISAs (R&D Systems).
Figure 5. Blocking antibody against MIP-3a abolishes the migration of
CD1a1 LC precursors induced by supernatant of activated keratinocyte.
Keratinocytes were seeded at 2 3 104 cells/ml, and after 5 d of culture
(80% confluence), cells were activated by IL-1b1TNF-a for 48 h. (A)
Transwell migration of CD341-derived CD1a1 LC precursors in re-
sponse to various concentrations of supernatants from resting or activated
keratinocytes is shown. Results are representative of five experiments. (B)
Transwell migration of CD1a1 LC precursors, in response to 1 mg/ml of
recombinant MIP-3a to 100 ng/ml of recombinant RANTES, or in re-
sponse to 25% of supernatant from resting or activated keratinocytes (Kc),
was assessed in the presence of 10 mg/ml mAb against MIP-3a or iso-
type-matched control (IgG1 Ctl). Values represent the mean of two inde-
pendent experimental determinations, and variations between the two
measurements were always ,10%. Results are expressed as migrating cell
numbers and are representative of three independent experiments.710 Inflammation-induced MIP-3a Recruits Langerhans Cell Precursors among DCs
Results
MIP-3a Is the Most Potent Chemokine That Selectively At-
tracts LC Precursors among DC Populations. As a way to un-
derstand the regulation of LC recruitment, we investigated
the response of CD341-derived LC precursors to various
chemokines. CD341 HPCs were cultured for 6 d in the
presence of GM-CSF1TNF-a1SCF, and the responses of
LC precursors were assessed by staining for CD1a (specific
marker for LCs in this system) after 1.5 h migration in 5-mm
transwells. Although the total population migrated in re-
sponse to several CC chemokines (MIP-1a, MIP-1b,
MCP-1–4, MIP-3a, RANTES; Fig. 1 A), the CD1a1 LC
precursors responded mainly to MIP-3a and to a lower
level to RANTES, MCP-3, and MIP-1a (Fig. 1 B). How-
ever, when dose–response analyses were performed, CD1a1
LC precursors migrated only in response to low doses of
MIP-3a (1–10 ng/ml; not shown). MIP-3a induced the
migration of CD341-derived CD1a1 LC precursors, but
not that of monocytes (not shown) and monocyte-derived
DCs or that of circulating blood DCs (Fig. 2 A). These
populations responded well to other chemokines such as
Figure 6. Upregulation of
MIP-3a mRNA and protein in
lesional psoriatic skin. Detection
of MIP-3a by in situ hybridiza-
tion (A, C, and E) and immuno-
histochemistry (B, D, F–L). J is a
higher magnification of I; B and
D, F, and H are serial cryostat
sections. Human skin sections
were hybridized with antisense
(A, C, and E) and sense (not
shown)  35S-labeled RNA probes
for MIP-3a and were exposed
for 40 d. By in situ hybridization,
no signal is detected in nonle-
sional (not shown) and in normal
skin (A). In lesional psoriatic
skin, MIP-3a mRNA is strongly
expressed within the suprabasal
layers of the epidermis (C; and E,
dark field illumination). The
sense riboprobes do not generate
any background hybridization
(not shown). In normal skin, im-
munostaining with MIP-3a–spe-
cific polyclonal antibody (red)
and anti-collagen IV mAb (blue)
reveals that MIP-3a protein is
very weakly expressed within the
stratum corneum (B). The speci-
ficity of this MIP-3a immu-
nostaining (red) was demonstrated
by preincubating the anti–MIP-
3a polyclonal antibody with the
recombinant MIP-3a protein
(D). Immunohistochemistry of
lesional psoriatic skin performed
with MIP-3a–specific poly-
clonal antibody (red) confirms
the upregulation of MIP-3a ex-
pression in the upper suprabasal
layers of the epidermis (F). Dou-
ble immunostaining performed
with MIP-3a–specific poly-
clonal antibody (red) and anti-
Langerin mAb (blue) reveals that
MIP-3a–expressing keratinocytes
colocalize with Langerin1 LCs
near the stratum corneum areas
(F) as well as around hair follicles
(G) of lesional psoriatic skin. The
specificity of MIP-3a immu-
nostaining (red) in lesional pso-
riatic skin was demonstrated (con-
tinues) 711 Dieu-Nosjean et al.
SDF-1 or MCP-1. In contrast, freshly isolated skin LCs
migrated in response to MIP-3a although to a lower level
than CD341-derived LC precursors, probably because they
may be in a more differentiated stage than in vitro–gener-
ated LC precursors. These chemotactic responses to MIP-
3a correlated with the expression of its receptor CCR6,
which was detected by FACS® analysis on CD341-derived
CD1a1 LC precursors and freshly isolated LCs but not on
other DC populations (Fig. 2 B).
These observations show that MIP-3a is the most potent
chemokine active on LC precursors and that it recruits only
LCs among freshly isolated DC populations.
MIP-3a Is Selectively Expressed at Epithelial Surfaces and Is
the Main Keratinocyte Chemoattractant for LC Precursors. In
accordance with our previous study on MIP-3a mRNA
expression (7), we confirmed the production of the protein
within the epithelial crypts of inflamed tonsils (Fig. 3,
A–C). The MIP-3a–expressing cells lined the lumen of the
crypt, at the interface between the external milieu and the
tissue, i.e., the site of pathogen entry. MIP-3a–positive
cells represented a subset of cells coexpressing cytokeratin
(Fig. 3 A) and E-cadherin (Fig. 3 B), demonstrating their
epithelial origin. Moreover, MIP-3a–expressing epithelial
cells colocalized with CD1a1 LCs within the inflamed
crypts (Fig. 3 C). Double staining on serial sections showed
that foci of high MIP-3a expression colocalized with areas
of agglomeration of CCR61 cells (Fig. 3 D).
Then, the cellular source of MIP-3a production was de-
termined using an ELISA specific for human MIP-3a (see
Materials and Methods). First, cell lines of epithelial origin
(renal cell carcinoma and colon carcinoma) constitutively
produced detectable amounts of MIP-3a (0.5–9.6 ng/ml),
whereas cell lines of other origin (melanoma, sarcoma,
neuroblastoma, fibroblasts, and T and B cells) did not (not
shown). On primary cultures (Fig. 4 A), MIP-3a was never
produced without activation by any cell types, including
epithelial cells. Upon activation with IL-1 and TNF-a (see
below), MIP-3a was produced by keratinocytes at high
level (40–90 ng/ml). Moderate levels of MIP-3a were pro-
duced by other cellular constituents of the skin such as IL-
11TNF-a–activated dermal endothelial cells (28–38 ng/
ml) and dermal fibroblasts (12–32 ng/ml). Low levels of
MIP-3a were secreted by monocyte-derived DCs (3–12
ng/ml), monocytes (4–10 ng/ml), and T cells (#1 ng/ml)
activated by CD40 ligand (CD40L), LPS, or anti-
CD31anti-CD28, respectively. Of note, IL-1b1TNF-a
stimulation did not induce the production of MIP-3a by
monocyte-derived DCs nor by monocytes (not shown).
Finally, B cells activated through CD40 did not secrete de-
tectable levels of MIP-3a.
The production of MIP-3a by epithelial cells was com-
pared with that of three other inducible chemokines,
MCP-1, RANTES, and MIP-1a, that are also active on
DCs and particularly on LC precursors (see Fig. 1). Nota-
bly, upon activation, MIP-3a was secreted by skin kerati-
nocytes in much larger amount (40–90 ng/ml) than the
other chemokines (RANTES 5 2–5 ng/ml, MCP-1 , 1
ng/ml, MIP-1a , 1 ng/ml) (Fig. 4 B). Supernatant from
unactivated keratinocytes did not induce the migration of
CD1a1 LC precursors (Fig. 5 A), in accordance with the
absence of MIP-3a production by using the specific MIP-3a
ELISA. In contrast, supernatants from cells activated with
IL-1b1TNF-a, at a concentration as low as 12.5% in-
duced a migration comparable to that observed with re-
combinant MIP-3a (1 mg/ml) (12.5% of the supernatant
corresponds to 10 ng/ml detected by the ELISA). Of note,
(continued) either by using isotype
controls (H) or by preincubating
the anti–MIP-3a polyclonal an-
tibody with the recombinant
MIP-3a protein (not shown). In
both conditions, no MIP-3a
staining is detected. Double
staining performed with anti-
Langerin mAb (blue) and anti–
DC-LAMP (red) indicates the
presence of a high number of
Langerin1DC-LAMP1 matur-
ing LCs (arrow) and
Langerin2DC-LAMP1 mature
DCs (arrowhead) in lesional pso-
riatic skin (I and J), whereas
Langerin1DC-LAMP2 LCs are
detected within the epidermis of
normal skin (not shown), lesional
(I), and nonlesional psoriatic skin
(K). Mature DCs (arrowhead)
and most of the maturing DCs
(arrow) that are present in the
dermis are detected around col-
lagen IV1 vessels (L). E, epider-
mis; D, dermis; C, stratum cor-
neum. Original magnifications:
(A, C, E–H, K, and L) 3200; (I)
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IL-1b and TNF-a, alone or in combination, had no
chemotactic effect in those assays. When anti–MIP-3a was
added with MIP-3a in the lower well, the migration in re-
sponse to this recombinant chemokine was abolished
whereas the antibody has no effect on the migration in-
duced by other chemokines such as RANTES (Fig. 5 B).
The effect of the keratinocyte supernatant on the migratory
response of CD1a1 LC precursors was suppressed in the
presence of anti–MIP-3a, whereas the control antibody has
no effect. In three independent experiments, activated ke-
ratinocyte supernatants induced a migration index of
CD1a1 LC precursors ranging from 5 to 20, and addition
of anti–MIP-3a always resulted in complete block of su-
pernatant activity. These results were confirmed with dif-
ferent cell types of epithelial origin (not shown).
Taken together, these observations show that MIP-3a is
expressed by epithelial cells at the site of pathogen entry,
and suggest that among the chemokines secreted by those
cells, MIP-3a plays a major role in the attraction of LC
precursors.
In Lesional Psoriatic Skin, the Upregulation of MIP-3a Ex-
pression Appears Associated with an Increased LC Turnover.
With regard to MIP-3a–selective expression in epithelium
and activity on LCs, we then investigated its expression in
skin, under normal and inflamed conditions. In normal
skin, MIP-3a mRNA was not detected by in situ hybrid-
ization (Fig. 6 A). However, a very weak expression of the
protein was detected by immunohistochemistry within the
stratum corneum (Fig. 6 B). As in normal skin, nonlesional
keratinocytes of the stratum corneum were the only cells
that expressed a very low level of MIP-3a protein (not
shown). However, in lesional psoriatic skin, MIP-3a was
upregulated in the suprabasal layers of the acanthotic epi-
dermis as shown by in situ hybridization (Fig. 6, C and E)
and by immunohistochemistry (Fig. 6, F and G). In all
samples (Fig. 6, D and H), the specificity of the MIP-3a
staining was demonstrated by the preincubation of the
anti–MIP-3a antibody with the recombinant MIP-3a pro-
tein (normal and lesional psoriatic skin shown).
When double staining was performed, accumulation of
Langerin1CD1a1 LCs was apparent adjacent to the site
of high MIP-3a expression (Fig. 6, F and G). Production
of MIP-3a protein was also observed around psoriatic hair
follicles, which were surrounded by Langerin1CD1a1 LCs
(Fig. 6 G). The sensitivity of the immunohistochemistry
technique did not permit the detection of CCR6 expres-
sion by inflammatory cells in the skin. We next analyzed
the maturation stage of epidermal DCs using mAbs against
Langerin and DC-LAMP, two DC-specific markers that
characterize immature and mature LCs, respectively (42,
43). In normal and in nonlesional psoriatic skin (Fig. 6 K,
and Fig. 7), epidermal Langerin1DC-LAMP2 cells rep-
resent the only LC population detected. In contrast,
Langerin1DC-LAMP1 maturing LCs are almost exclu-
sively observed in lesional psoriatic skin, mainly in the der-
mis but also in the epidermis and the papillary dermis (Fig.
6, I and J, and Fig. 7). Langerin1DC-LAMP1 maturing
LCs represent .25% of the LC compartment in lesional
psoriatic skin, whereas they represent ,2% in nonlesional
psoriatic and normal skin (Fig. 7). Furthermore, Langerin2
DC-LAMP1 mature DCs were only found in the dermis of
lesional skin (20% of total DC population; Fig. 6, J–L, and
Fig. 7), and they are associated with a veiled morphology
(Fig. 6 J). Finally, maturing and mature DCs that are local-
ized in the dermis were always observed around collagen
IV1 vessels (Fig. 6 L). Some of these vessels probably repre-
sent lymphatic vessels, suggesting that maturing LCs emi-
grate out of the skin. Thus, the presence of mature LCs
in the epidermis and dermis in the local inflammatory pso-
riatic skin environment is likely to reflect a high LC turn-
over.
Taken together, these observations argue for an active
role of MIP-3a in this suggested increase in LC trafficking
Figure 7. Maturing DC-LAMP1 LCs are strongly increased in lesional
psoriatic skin. The stage of DC maturation was determined according to
the expression by immunohistochemistry of two DC-specific markers,
Langerin and DC-LAMP. Immature LCs (DC-LAMP2Langerin1,
present in epidermis only), maturing LCs (DC-LAMP1Langerin1,
present in epidermis and dermis), and mature DCs (DC-LAMP1
Langerin2, present in dermis only) were counted in three randomly se-
lected fields (original magnification: 3100) per section. Each count was
performed on two or three serial sections, and results were expressed as
the mean 6 SD of DCs per three fields. Results from three to four inde-
pendent normal donor and patients are shown. PSO., psoriatic.713 Dieu-Nosjean et al.
in lesional psoriatic skin and, thus, in the development
and/or chronicity of this disease.
MIP-3a Production Is Induced upon Inflammatory and T Cell
Signals. The regulation of MIP-3a secretion by epithelial
cells was further defined by using the kidney carcinoma ep-
ithelial cell lines expressing this chemokine at different lev-
els. In vitro, among several inflammatory stimuli (IL-1, IL-6,
TNF-a, and GM-CSF), only IL-1a and IL-1b induced a
strong production of MIP-3a in all the epithelial cells
tested, as shown with CHA and VER (Fig. 8 A). However,
TNF-a synergized with IL-17 and in some experiments
with IL-1 in inducing MIP-3a production. The optimal
production was obtained with 1 ng/ml of IL-1 after 24 h of
activation (Fig. 8 B). Because in psoriasis, T cells are in-
volved in the development of the pathology, we next
tested the effect of signals delivered by T lymphocytes on
MIP-3a production by epithelial cells (Fig. 8 C). On the
epithelial cell line CHA, MIP-3a was not detected in ab-
sence of activation nor after activation with IFN-g or
CD40L alone. However, CD40L synergized with both IL-1
(from 70 to 234 ng/ml) and IL-17 (from 1 to 19 ng/ml).
CD40L and IFN-g also had a strong synergic effect on
MIP-3a production (28 ng/ml) compared with the cyto-
kines alone. We also observed (Fig. 8 C) that coculture of
anti-CD3–activated T cells with CHA induced the secre-
tion of MIP-3a at a physiologic and chemotactic level
(15.7 ng/ml).
Altogether, these observations show that upon inflam-
matory or T cell signals, the production of MIP-3a is
strongly upregulated by cells of epithelial origin.
Discussion
The capacity of DCs to reach the site of injury/infection
and consequently to initiate immunity is determined by
their ability to respond to selected chemokines. In this
study, we show that MIP-3a is a major chemokine pro-
duced by activated epithelial cells, and selectively active on
LCs and their precursors. MIP-3a’s unique activity sug-
gests that it plays a key role in the control of LC recruit-
ment at inflamed epithelial surfaces and in the regulation of
epithelial immunity.
Among all CC chemokines tested, MIP-3a appears to
be the most potent chemokine inducing the migration of
LC precursors and freshly isolated LCs but not of any other
DC population. This result is in line with the specific ex-
pression of CCR6 by cells of the LC lineage in contrast
with other receptors such as CCR1, CCR2, and CCR5
that are expressed on several other DC populations (9, 34;
and Caux, C., manuscript in preparation). This observation
is in accordance with previous reports showing that both
CCR6 expression and MIP-3a responsiveness were de-
tected on CD341-derived DCs but not on monocyte-
derived DCs (36, 44). So far, no DC or DC precursors ex-
pressing CCR6 or responding to MIP-3a have been
identified in the blood from healthy donors. However, it
has been recently shown that monocyte-derived DCs can
express CCR6 and respond to MIP-3a when cultured
with TGF-b (45), a factor previously reported to support
LC differentiation from monocytes (46) or from a subset of
blood DCs (47). This might suggest that the LC precursors
in the bloodstream are not the target of MIP-3a but they
acquire MIP-3a responsiveness when they are already mo-
bilized in the tissue and undergo differentiation events in
the local cytokine microenvironment (48). This indicates
that chemokines play a role not only in the intracellular ex-
travasation across the endothelial barrier, but also in the
cellular migration across tissues. Alternatively, in normal
condition, LC precursors might not exist in sufficient num-
Figure 8. Regulation of MIP-3a production by epithelial cells in re-
sponse to inflammatory cytokines or T cell signals. (A) Two renal carci-
noma cell lines, CHA and VER, were seeded at 1–2 3 104 cells/ml, and
after 1–3 d of culture (80% confluence), cells were either activated by IL-
1a, IL-1b, IL-6, and IL-17 or left unactivated, with or without stimula-
tion by TNF-a for 48 h. (B) Renal carcinoma cell line, CHA, was seeded
at 1–2 3 104 cells/ml, and after 1–3 d of culture (80% confluence), cells
were either activated by IL-1b or left unactivated, in a dose dependent on
IL-1b (left) or in a time-dependent manner (right). (C) Renal carcinoma
cell line, CHA, was seeded at 1–2 3 104 cells/ml, and after 1–3 d of cul-
ture (80% confluence), cells were either activated by IL-1b, IL-17, IFN-g,
or left unactivated, with or without stimulation by CD40L L cells for 48 h.
Peripheral blood T cells and renal carcinoma cell line (CHA) were inde-
pendently or cocultivated in the presence or in absence of anti-CD3 anti-
bodies for 48 h. Supernatants were collected and measured for MIP-3a
content using a specific ELISA. Results are representative of five indepen-
dent experiments.714 Inflammation-induced MIP-3a Recruits Langerhans Cell Precursors among DCs
bers to be detected in the circulation. But, upon inflamma-
tory conditions, cytokines such as GM-CSF may be re-
leased, reach the bone marrow, and induce the margination
of LC precursors, which can then be recruited by local
MIP-3a secretion.
The selective role of MIP-3a in the recruitment of LC
precursors at epithelial surfaces was further supported by (a)
its restricted expression by inflamed epithelium at mucosal
and nonmucosal sites in vivo; (b) a colocalization of MIP-3a
production and the presence of LCs, in situ; and (c) its
strong inducible secretion by epithelial cells in response to
inflammatory mediators or T cell signals in vitro. In line
with the expression of MIP-3a at epithelial surfaces in
vivo, the expression of MIP-3a mRNA has been reported
in the intestinal mucosa in both mice and humans (49). Ex-
periments with activated keratinocyte supernatants demon-
strate that MIP-3a is the main chemokine secreted by epi-
thelial cells under inflammatory conditions that is able to
attract LC precursors. Our study is in agreement with the
recent publication of Charbonnier and colleagues (50)
demonstrating the unique capacity of MIP-3a to induce
LC migration. However, in normal skin, they detected the
MIP-3a protein in the basal and suprabasal layers of the
epidermis, whereas we did not see any expression in those
regions by in situ hybridization or by immunohistochemis-
try. Then, they suggested a role of MIP-3a in the constitu-
tive recruitment of LCs into the skin. As we have detected
a very low but specific MIP-3a staining within the stratum
corneum, we do not exclude a putative role of this
chemokine in LC trafficking under normal conditions. In
this context, it would be interesting to determine if MIP-3a
secretion can be detected during terminal differentiation of
keratinocytes in vitro. However, we observed a strong up-
regulation of MIP-3a secretion in vitro after inflammatory
and T cell signals as well as in vivo, at inflammatory sites
such as in tonsils and in lesional psoriatic skin, suggesting a
key role of MIP-3a in the recruitment of LC precursors at
sites of inflammation. Furthermore, this hypothesis is in
agreement with: (a) the upregulation of MIP-3a mRNA
observed after in vivo injection of LPS (49); and (b) the
presence of LCs in the skin of CCR6-deficient mice in
normal situation (51). Thus, it is tempting to consider that
MIP-3a may have a more crucial role in the recruitment of
epidermal LCs in inflammatory conditions that strongly in-
duce its expression than in their constitutive trafficking.
We report here that MIP-3a is strongly upregulated in
lesional psoriatic skin in association with a consistent pool
of maturing LCs (DC-LAMP1) concentrated around ves-
sels, arguing for an active role of MIP-3a in an increase of
LC trafficking. Furthermore, in this pathology, T cells are
responsible for the development of the lesions through the
activation of keratinocytes (52–54). In this context, MIP-3a
expression colocalizes with memory T cells within lesional
psoriatic skin and CCR6 expression is upregulated both in
lesional biopsies and in peripheral blood cells (55). Further-
more, MIP-3a has been reported to be active on memory
T cells with either epithelial or gut-homing properties (56,
57), and on intestinal g/d T cells (49). Altogether, these
observations suggest that MIP-3a through the recruitment
of both LCs and T cells of epithelial tropisms may have a
unique role in the regulation of epithelial immunity, and
may participate in epithelial immune disorders such as pso-
riasis.
MIP-3a was also expressed by most tumor cell lines of
epithelial origin (renal adenocarcinoma and colon adeno-
carcinoma, among others), and detection of MIP-3a secre-
tion in specimens of tumors such as breast adenocarcinoma
(not shown; references 58–60) suggests that MIP-3a can be
produced by tumor cells in vivo. We and others (61–63)
have previously shown that adenocarcinomas, in particular
renal cell carcinomas, can alter DC development/matura-
tion, preventing the appearance of their T cell stimulatory
function. This suggests that tumors of epithelial origin pro-
ducing MIP-3a can attract LC precursors and divert their
function to escape immune surveillance and reach a state of
tolerance.
Although, MIP-3a appears to have a single receptor,
CCR6, the defensins-b which are also expressed in the ep-
ithelium have been demonstrated recently to bind to
CCR6 (64). The unique role of CCR6 ligands in the re-
cruitment of LC precursors offers novel approaches to as-
sess for the functions of LCs and possibly to manipulate
them.
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